Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study.
Davide MascarellaGiorgia AndriniBaraldi CarloClaudia AltamuraValentina FavoniFlavia Lo CastroGiulia PierangeliFabrizio VernieriSimona GuerzoniSabina CevoliPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2024)
The study concludes that treatment with anti-CGRP mAbs over one year does not significantly affect BP in patients aged ≥ 60, nor does it increase the incidence of hypertension compared to general population trends. Nonetheless, continuous monitoring and further long-term studies are necessary to fullya scertain the cardiovascular safety of these medications in the elderly.
Keyphrases
- blood pressure
- monoclonal antibody
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- middle aged
- community dwelling
- peritoneal dialysis
- risk factors
- prognostic factors
- hypertensive patients
- heart rate
- type diabetes
- patient reported outcomes
- weight loss
- adipose tissue
- combination therapy
- skeletal muscle
- patient reported
- smoking cessation